Paclitaxel-fatty acid prodrug and self-microemulsification preparation and preparation method and application thereof

By introducing the tumor microenvironment sensitive disulfide bond linkage and fatty acid part into paclitaxel, a self-micromilk preparation is formed, which solves the problem of poor oral absorption of paclitaxel, and achieves efficient and low-toxic anti-cancer drug delivery and target site specific release. It significantly improves oral bioavailability and chemotherapy effects.

CN116514743BActive Publication Date: 2024-11-29SHENYANG PHARMA UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202210063800.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-01-20
Publication Date
2024-11-29
Estimated Expiration
2042-01-20

AI Technical Summary

Technical Problem

As a polar molecule that is difficult to dissolve in water, its poor solubility and permeability, P-gp efflux and liver first pass effect limit its oral bioavailability, resulting in poor oral administration effect. Some fatty acid prodrugs are not effective when hydrolyzed and ruptured.

Method used

A paclitaxel-fatty acid prodrug was designed to form a paclitaxel-fatty acid prodrug and prepared into a microemulsion preparation by introducing chemical linkages that are sensitive to the tumor microenvironment, such as reducing sensitive disulfide bonds. , leverage the properties of fatty acids to improve the oral utilization of drugs and the specific release of target sites.

Benefits of technology

It improves the oral bioavailability and chemotherapy sensitivity of paclitaxel, achieves efficient and low-toxic anti-cancer drug delivery, simplifies the preparation process, avoids gastrointestinal toxicity, and significantly improves the stability and absorption characteristics of the drug.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116514743B_ABST
    Figure CN116514743B_ABST
Patent Text Reader

Abstract

Paclitaxel-fatty acid prodrug and self-microemulsification preparation and its preparation method and application belong to the field of medical technology. The present invention provides a self-microemulsification preparation of paclitaxel-fatty acid prodrug, comprising paclitaxel-fatty acid prodrug and excipients, wherein the excipients include an oil phase, an emulsifier, a short-chain alcohol or an ether emulsifier, and by weight percentage, the oil phase accounts for 10%-70% of the self-microemulsification preparation, the emulsifier accounts for 15%-85% of the self-microemulsification preparation, and the short-chain alcohol or ether emulsifier accounts for 0%-35% of the self-microemulsification preparation; the paclitaxel-fatty acid prodrug accounts for 1-10% of the total weight of the excipients. The paclitaxel-fatty acid prodrug and the self-microemulsification preparation of the present invention improve oral availability and improve the chemotherapeutic sensitivity of anticancer drugs. The preparation is uniform and stable, the preparation process is simple, and it is easy to industrialize. The general formula of paclitaxel-fatty acid prodrug is shown as follows:
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical technology, and specifically relates to paclitaxel-fatty acid prodrug and self-microemulsification preparation and application thereof in oral chemotherapy. Background Art

[0002] Cancer seriously threatens human health and has become the main cause of death. Paclitaxel (PTX) has been used as a first-line chemotherapy drug since it was discovered in the 1960s and is widely used in the clinical treatment of various cancers. Paclitaxel is a polar molecule that is poorly soluble in water. The most widely used clinical application is the injection of paclitaxel, Taxol. This preparation uses polyoxyethylene castor oil and ethanol to solubilize paclitaxel, which causes patients to have serious excipient-related toxic side effects, and its clinical application is greatly limited. Oral administration, as the most commonly used method of administration, has many advantages such as convenient administration, low treatment cost, and high patient compliance. Compared with intravenous administration, it can improve its drug absorption and distribution characteristics, thereby reducing the toxic side effects caused by the rapid entry of high-dose drugs into the blood and increasing the frequency of administration. However, the poor solubility and permeability of paclitaxel, P-gp efflux, and hepatic first-pass effect all limit its oral bioavailability. Therefore, the development of paclitaxel oral preparations with high efficiency, low toxicity, and high oral bioavailability remains a hot topic of research.

[0003] Fatty acids are essential fatty acids for the human body, which maintain many normal physiological functions of the human body. In addition, tumor cells also have a higher demand for fatty acids than normal cells, so fatty acids have a natural "nutritional targeting" effect on tumor cells, and are widely used in the design of prodrugs to improve the drugability of drugs and increase drug delivery efficiency. But fatty acids also have defects, because they are fat-soluble molecules, and it is difficult for the parent drug to hydrolyze and break from the fat-soluble prodrug, which will result in poor efficacy. Therefore, it is necessary to introduce a chemical linker arm that is sensitive to the tumor microenvironment into the structure of fatty acid-anticancer drug prodrugs.

[0004] Self-microemulsifying drug delivery system (SMEDDS) has become the best carrier for delivering lipid prodrugs due to its advantages such as simple preparation process, high drug loading, and easy process scale-up. This drug delivery system can promote the absorption of drugs by the gastrointestinal tract and improve the bioavailability of drugs. However, there are still some problems with self-microemulsification, such as limited improvement in oral bioavailability and gastrointestinal toxicity. Therefore, it is very necessary to design a safe and simple oral dosage form of fatty acid prodrugs. Summary of the invention

[0005] In view of the problem of poor oral absorption of paclitaxel, the present invention provides a paclitaxel-fatty acid prodrug, and prepares the prodrug into a self-microemulsification preparation of paclitaxel-fatty acid prodrug, which can promote lymphatic transport of poorly soluble drugs, improve their oral availability, and improve the chemotherapy sensitivity of anticancer drugs. On this basis, a chemical linker sensitive to the tumor microenvironment is introduced into the structure of the anticancer drug-fatty acid prodrug, which promotes oral absorption of the anticancer drug and enables it to be specifically released at the target site, achieving the effect of high efficiency and low toxicity.

[0006] The first object of the present invention is to provide a paclitaxel-fatty acid prodrug as shown in formula (I) or its geometric isomers, pharmaceutically acceptable salts, hydrates, solvates; paclitaxel is connected to the fatty acid part through a tumor-sensitive bond such as a reduction-sensitive disulfide bond to obtain a paclitaxel-fatty acid prodrug;

[0007]

[0008] Wherein, R is a substituted or unsubstituted, branched or linear fatty alkyl group containing 1 to 30 carbon atoms. The paclitaxel may be a taxane compound.

[0009] A specific paclitaxel-oleic acid prodrug or its geometric isomers or pharmaceutically acceptable salts as shown in formula (II):

[0010]

[0011] A paclitaxel-linoleic acid prodrug represented by formula (III) or its geometric isomers or pharmaceutically acceptable salts:

[0012]

[0013] The second object of the present invention is to provide a method for preparing the above-mentioned paclitaxel-fatty acid prodrug. The specific preparation method is as follows:

[0014] (a) The fatty acid is dissolved in an organic solvent and reacted with ethylene glycol under the catalysis of p-toluenesulfonic acid to obtain an intermediate product 1;

[0015] (b) dissolving 2,2'-dithiodiacetic anhydride in an organic solvent and reacting with the intermediate product 1 in the presence of HOBT, EDCI and DMAP to obtain the intermediate product 2;

[0016] (c) The intermediate product 2 is subjected to an esterification reaction with paclitaxel under the catalytic conditions of HOBT and EDCI, and the paclitaxel-fatty acid prodrug is separated and purified.

[0017] The synthetic route of oleic acid is as follows:

[0018]

[0019] The third object of the present invention is to provide a simple and safe pharmaceutical composition containing paclitaxel-fatty acid prodrug. The pharmaceutical composition is a self-microemulsification preparation of paclitaxel-fatty acid prodrug, comprising paclitaxel-fatty acid prodrug and excipients. The excipients include emulsifiers, short-chain alcohols or ethers emulsifiers, and oil phase. By weight percentage, the oil phase accounts for 10%-70% of the self-microemulsification preparation, the emulsifier accounts for 15%-80% of the self-microemulsification preparation, the short-chain alcohols or ethers emulsifiers account for 0%-35% of the self-microemulsification preparation; and the paclitaxel-fatty acid prodrug accounts for 1%-10% of the total amount of the excipients.

[0020] Preferably, in the pharmaceutical composition of the present invention, by weight percentage, the oil phase accounts for 10%-65% of the self-microemulsification preparation, the emulsifier accounts for 20%-80% of the self-microemulsification preparation, the short-chain alcohol or ether emulsifier accounts for 0%-30% of the self-microemulsification preparation, and the paclitaxel-fatty acid prodrug accounts for 1%-8% of the total amount of excipients.

[0021] Further preferably, in the pharmaceutical composition of the present invention, by weight percentage, the oil phase accounts for 10%-60% of the self-microemulsification preparation, the emulsifier accounts for 25%-80% of the self-microemulsification preparation, and the paclitaxel-fatty acid prodrug accounts for 1%-5% of the total amount of excipients.

[0022] Furthermore, the weight ratio of the oil phase, the emulsifier, and the short-chain alcohol or ether co-emulsifier is: 3:(10-20):(2-6).

[0023] The oil phase is long-chain triglycerides, mixed long-chain glycerides, medium-chain triglycerides or a combination thereof, preferably monoolein, monolinolein, caprylic capric macrogol glyceride, oleic acid macrogol glyceride, tricaprylin and commercial forms of the above excipients, such as one or more of Maisine 35-1, Peceol and Labrasol; more preferably monolinolein.

[0024] The short-chain alcohol or ether emulsifier is one of diethylene glycol monoethyl ether, propylene glycol monocaprylate, propylene glycol, and glycerol, preferably diethylene glycol monoethyl ether.

[0025] The emulsifier is a polyoxyethylene sorbitan fatty acid ester compound, including but not limited to polyoxyethylene sorbitan ester 80, 20, 60, which are trade names Tween 80, Tween 20, Tween 60 respectively; polyoxyethylene castor oil compounds, including but not limited to polyoxyethylene 35 castor oil, polyoxyethylene 40 hydrogenated castor oil and polyoxyethylene 60 hydrogenated castor oil, which are trade names / Kolliphor EL, RH40, RH60; polyoxyethylene alkyl ethers, including but not limited to polyoxyethylene 20 cetyl stearyl ether and polyoxyethylene 10 oleyl ether; DL-.α.-tocopheryl polyethylene glycol succinate; mono-, di- and tri-glycerides; mono-, di- and tri-glycerides of C8-C22 fatty acids; sucrose mono-, di- and tri-esters; sodium sulfosuccinate dioctanoate; polyoxyethylene-polyoxypropylene copolymers, including but not limited to poloxamer 124, poloxamer 188, and poloxamer 407; polyoxyethylene ethers of C8-C22 fatty alcohols, including but not limited to polyoxyethylene lauryl alcohol, polyoxyethylene cetyl alcohol, polyoxyethylene stearyl alcohol, and polyoxyethylene oleyl alcohol, which are sold under the trade names of, for example, 35. 58. 78. 98; or a mixture of any two or more thereof. Tween 80 can improve the uptake of P-gp substrate peptide by cells, so Tween 80 is selected as the emulsifier in the technical solution of the present invention.

[0026] The method for preparing the self-microemulsification preparation of paclitaxel-fatty acid prodrug of the present invention is prepared by the following method:

[0027] The paclitaxel-fatty acid prodrug, short-chain alcohol or ether emulsifier, emulsifier and oil phase are mixed, and the auxiliary materials and the prodrug are uniformly mixed by ultrasound to obtain the paclitaxel-fatty acid prodrug self-microemulsification preparation.

[0028] When the oil phase is monolinoleyl glycerol, the emulsifier is Tween 80, the short-chain alcohol or ether emulsifier is diethylene glycol monoethyl ether, and the oil phase accounts for 10%-70% of the self-microemulsification preparation, the emulsifier accounts for 15%-80% of the self-microemulsification preparation, and the short-chain alcohol or ether emulsifier accounts for 0%-35% of the self-microemulsification preparation, the obtained paclitaxel-fatty acid prodrug self-microemulsification preparation has the best particle size and particle size distribution, has the best stability, and can significantly improve the oral bioavailability of paclitaxel.

[0029] The present invention uniformly mixes monolinoleylglycerol, Tween 80 and diethylene glycol monoethyl ether for the first time to prepare a blank self-microemulsification preparation, and dissolves the synthesized tumor microenvironment sensitive paclitaxel-fatty acid prodrug into the blank self-microemulsification preparation to prepare a self-microemulsification preparation of paclitaxel-fatty acid prodrug. The preparation method of the self-microemulsification preparation is simple, and does not require probe ultrasound, high temperature heating and other processes, and only requires simple stirring or ultrasonic dissolution, and the process is simple, easy to industrialize, and has strong repeatability; the obtained self-microemulsification preparation is a clear and transparent emulsion with blue opalescence, and the thermodynamically unstable state of the nano preparation is relatively stable, and the self-microemulsification preparation provided by the present invention is easy to store; the excipients used in the self-microemulsification preparation provided by the present invention are all FDA-approved pharmaceutical excipients, and will not cause gastrointestinal toxicity after oral administration; in addition, the self-microemulsification preparation is highly suitable for the designed paclitaxel-fatty acid prodrug, and significantly improves the oral bioavailability of paclitaxel.

[0030] Application of the paclitaxel-fatty acid prodrug or the self-microemulsification preparation of paclitaxel-fatty acid prodrug of the present invention in oral administration.

[0031] Application of the paclitaxel-fatty acid prodrug or the self-microemulsification preparation of paclitaxel-fatty acid prodrug in the preparation of anti-tumor drugs.

[0032] Application of the paclitaxel-fatty acid prodrug or the self-microemulsification preparation of paclitaxel-fatty acid prodrug in a drug delivery system.

[0033] The advantages of the present invention are:

[0034] 1. Based on the properties of fatty acids, the present invention designs paclitaxel-fatty acid prodrugs, improves the delivery efficiency of paclitaxel, and enhances the in vivo stability of anticancer drugs.

[0035] 2. The present invention uses a disulfide bond bridge that is sensitive to the tumor microenvironment to connect fatty acids and poorly soluble drugs, so that the drugs can be specifically released at the target site, achieving the effect of high efficiency and low toxicity.

[0036] 3. The self-microemulsification preparation prepared by the present invention is easy to prepare and produce, has ideal physical and chemical stability, and good biocompatibility. Compared with the nanoemulsion in the prior art, the preparation process is simplified, and there is no heating process and probe ultrasound. It promotes the lymphatic transport of paclitaxel, avoids the first-pass effect, and thus improves the oral absorption of chemotherapeutic drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is the high-resolution mass spectrum of paclitaxel-oleic acid prodrug.

[0038] Figure 2 Paclitaxel-oleic acid prodrug 1 H-NMR spectrum.

[0039] Figure 3 This is the high-resolution mass spectrum of paclitaxel-linoleic acid prodrug.

[0040] Figure 4 Paclitaxel-linoleic acid prodrug 1 H-NMR spectrum.

[0041] Figure 5 is the solubility of paclitaxel-fatty acid prodrug in different excipients.

[0042] Figure 6 Screening pseudo-ternary phase diagram for self-microemulsion of paclitaxel-fatty acid prodrug.

[0043] Figure 7 This is the concentration-time curve of paclitaxel-fatty acid prodrug self-microemulsion preparation in pharmacokinetic experiment.

[0044] FIG8 is a graph showing an in vivo oral antitumor experiment of paclitaxel-fatty acid prodrug self-microemulsion formulation; A: tumor growth curve, B: mouse body weight change graph, C: tumor-bearing rate. DETAILED DESCRIPTION

[0045] The present invention is further described by the following examples, but is not limited thereto.

[0046] Example 1

[0047] Preparation of Paclitaxel-Oleic Acid Prodrug (PTX-SS-OA) and Paclitaxel-Linoleic Acid Prodrug (PTX-SS-LA)

[0048] The structure is as follows:

[0049]

[0050] (a) 0.84 g (4.74 mmol) of oleic acid was dissolved in 2 mL of toluene, and then slowly dripped into a reaction bottle containing 15.30 mL (0.14 mol) of ethylene glycol and 0.17 g (0.47 mmol) of p-toluenesulfonic acid, and the reaction was continued for 2 h. The reaction solution was extracted with toluene, washed once with a saturated NaHCO3 solution, dried over anhydrous sodium sulfate, and the solvent was removed by rotary evaporation. Column chromatography was used for separation and purification under the conditions of n-hexane:ethyl acetate (volume ratio 50:1-20:1, 1‰ glacial acetic acid) to obtain intermediate 1.

[0051] (b) 0.25 g (0.77 mmol) of intermediate 1 was dissolved in 5 mL of dichloromethane. Meanwhile, 0.19 g (1.16 mmol) of 2,2'-dithiodiacetic anhydride was placed in an eggplant-shaped bottle. 20 mL of dichloromethane, 1.16 mmol of HOBt, 1.16 mmol of EDCI and 0.077 mmol of DMAP were added. Then, the solution in the eggplant-shaped bottle was slowly added dropwise to the dichloromethane solution containing intermediate 1. The mixture was stirred for 30 min and allowed to react overnight at room temperature. The mixture was extracted with CH2Cl2. The extract was washed with saturated NaCl solution 3 times and dried over anhydrous sodium sulfate. The solvent was removed by rotary evaporation. The intermediate 2 was separated and purified by column chromatography. The separation conditions were cyclohexane:acetone (volume ratio 30:1-10:1).

[0052] (c) 0.14 g (0.31 mmol) of intermediate 2, 0.05 g (0.26 mmol) of EDCI, 0.035 g (0.26 mmol) of HOBt and 0.22 g (0.25 mmol) of paclitaxel were placed in an eggplant-shaped bottle, 25 mL of CH2Cl2 was added, and the reaction was carried out at room temperature under nitrogen protection for 12 h. The extract was washed with saturated NaCl solution three times, dried over anhydrous sodium sulfate, filtered, and the solvent was removed by rotary evaporation. The product was separated and purified by high-efficiency preparative liquid phase (the preparative liquid phase condition was pure acetonitrile) to obtain PTX-SS-OA.

[0053] The molecular weight of the paclitaxel-oleic acid prodrug prepared in Example 1 was determined by high resolution mass spectrometry. Figure 1 shown.

[0054] use 1 H-NMR spectrum was used to determine the structure of the paclitaxel-oleic acid prodrug prepared in Example 1. The solvent used was DMSO. The results are as follows: Figure 2 Corresponding characteristic peak analysis: the characteristic peaks of paclitaxel are δ9.20 (d, J = 8.3 Hz, 1H), 7.71 (dt, J = 30.3, 7.5 Hz, 3H), 7.60–7.40 (m, 7H), the characteristic peaks of the connecting bond are 4.30–4.17 (m, 4H), and the characteristic peaks of oleic acid are 1.35–1.22 (m, 17H), 1.01 (d, J = 10.7 Hz, 6H), 0.85 (t, J = 6.6 Hz, 3H).

[0055] Oleic acid is replaced with linoleic acid, and the synthesis steps are the same as the synthesis method of paclitaxel-oleic acid prodrug to obtain PTX-SS-LA.

[0056] The molecular weight of the prepared paclitaxel-linoleic acid prodrug was determined by high resolution mass spectrometry. Figure 3 shown.

[0057] use 1H-NMR spectrum was used to determine the structure of the paclitaxel-linoleic acid prodrug. The solvent used was DMSO. The results are shown in Figure 4 Corresponding characteristic peak analysis: the characteristic peaks of paclitaxel are δ9.20 (d, J = 8.3 Hz, 1H), 7.71 (dt, J = 30.3, 7.3 Hz, 3H), 7.60–7.40 (m, 7H), the characteristic peaks of the linker arm are 4.31–4.17 (m, 4H), and the characteristic peaks of linoleic acid are 1.26 (d, J = 16.7 Hz, 22H), 1.01 (d, J = 10.7 Hz, 6H), 0.85 (dd, J = 7.8, 5.5 Hz, 3H).

[0058] Example 2

[0059] Optimization of formulation of paclitaxel-fatty acid prodrug self-microemulsion formulation

[0060] The oral absorption of paclitaxel-fatty acid prodrug is highly dependent on lipid digestion. Self-microemulsifying drug delivery system (SMEDDS) is an ideal carrier for poorly soluble, poorly absorbed, lipid-soluble and easily hydrolyzed drugs. SMEDDS has unique advantages, such as high drug loading and easy to scale up production.

[0061] 2.1 Prescription screening of paclitaxel-fatty acid prodrug self-microemulsion preparation

[0062] 2.1.1 Selection of oil phase

[0063] In order to ensure the drug loading of the self-microemulsification preparation, the solubility of paclitaxel-fatty acid prodrug in several oil phases was measured. 200 mg of paclitaxel-oleic acid prodrug prepared in Example 1 was weighed and added to 1 g of Peceol (monoolein), 1 g of Maisine35-1 (monolinolein), 1 g of Labrasol (caprylic capric acid macrogol glyceride), 1 g of LabrafilM1944CS (oleic acid macrogol glyceride), and 1 g of MCT (tricaprylin). The mixture was vortexed for 30 seconds, shaken for 48 hours to reach equilibrium, centrifuged for 30 minutes, 10 μL of the upper layer liquid was taken, diluted with 1 mL of acetonitrile, filtered with a filter membrane, and the filtrate was sampled and the solubility was measured. The results are as follows: Figure 5 According to the solubility results, the prodrug solubility is highest when monolinoleylglycerol is selected as the oil phase, so monolinoleylglycerol is preferably used as the oil phase of the paclitaxel-fatty acid prodrug self-microemulsion preparation.

[0064] 2.1.2 Selection of emulsifier

[0065] The solubility results are as follows Figure 5As shown in the figure, since the addition of Tween 80 can improve the uptake of P-gp substrate peptide by cells, and a large number of literature reports that Tween 80 can promote drug lymphatic transport, Tween 80 is selected as the emulsifier for the paclitaxel-fatty acid prodrug self-microemulsion preparation.

[0066] 2.1.3 Emulsifier

[0067] Transcutol HP (diethylene glycol monoethyl ether) and Capryol 90 (propylene glycol monocaprylate) were selected as the emulsifiers. The solubility of paclitaxel-oleic acid prodrug in different emulsifiers was determined according to the method in step 2.1.1. The results are as follows: Figure 5 According to the solubility results, when diethylene glycol monoethyl ether is selected as the co-emulsifier, the solubility of paclitaxel-fatty acid prodrug is the largest and the best drug loading amount can be obtained.

[0068] 2.2 Drawing of pseudo three-phase diagram

[0069] A pseudo-ternary phase diagram was established to find the most suitable ratio of the three terms. The specific self-microemulsification region was determined in the pseudo-ternary phase diagram by visual observation. Figure 6 When the proportion of the oil phase is 10%-60%, the proportion of the emulsifier is 25%-80%, and the proportion of the co-emulsifier is 0%-30%, a self-microemulsion can be formed.

[0070] Example 3

[0071] Preparation of Paclitaxel-Fatty Acid Prodrug Self-Microemulsion Formulation

[0072] 3.1 Preparation and optimization of blank self-microemulsification preparation

[0073] The oil phase, emulsifier, short-chain alcohol or ether emulsifier were mixed, and the auxiliary materials were mixed evenly by ultrasound. Monolinoleic acid glyceryl was selected as the oil phase, Tween 80 was selected as the emulsifier, and diethylene glycol monoethyl ether was selected as the short-chain alcohol or ether emulsifier. A series of self-microemulsification preparations with different proportions were prepared according to Table 1. 1 mL of the above self-microemulsification stock solution was added to 10 mL of distilled water and stirred. The appearance and transparency of the emulsified system were used as evaluation indicators.

[0074] When the content of monolinoleyl glycerol is 10%-70%, Tween 80 is 15%-80% and diethylene glycol monoethyl ether is 0%-35%, a uniform and stable self-microemulsification preparation can be formed, and the particle size thereof is less than 300nm.

[0075] When the content of monolinoleyl glycerol is 10%-65%, Tween 80 is 20%-80% and diethylene glycol monoethyl ether is 0%-30%, a uniform and stable self-microemulsification preparation can be formed, and the particle size thereof is less than 300nm, which is conducive to in vivo absorption.

[0076] When the content of monolinoleyl glycerol is 10%-60%, Tween 80 is 25%-80% and diethylene glycol monoethyl ether is 0%-30%, a uniform and stable self-microemulsification preparation can be formed, and the particle size thereof is less than 250nm, which is most conducive to in vivo absorption.

[0077] The self-microemulsification preparations of each formulation remained uniform and stable at 15 days without stratification and precipitation, and had good stability.

[0078] It can be seen that under the conditions of satisfying the polydispersity index (PDI) < 0.4 and the minimum particle size, the weight ratio of monolinoleylglycerol / Tween 80 / diethylene glycol monoethyl ether was determined to be 3:15:4, which was used as the optimized self-microemulsification formula for further research.

[0079] Table 1 Characterization of emulsions with different proportions of excipients

[0080]

[0081]

[0082] 3.2 Preparation and characterization of paclitaxel-fatty acid prodrug self-microemulsion formulation

[0083] When the weight ratio of monolinoleylglycerol / Tween 80 / diethylene glycol monoethyl ether is 3:15:4, the particle size, PDI and drug loading of PTX-SS-OA SMEDDS, PTX-SS-LA SMEDDS and PTX self-microemulsification preparation (PTX SMEDDS) are measured. The results are shown in Table 2. It can be seen that the drug loading capacity of the two groups of prodrugs (PTX-SS-OA and PTX-SS-LA) is significantly improved compared with PTX, indicating that the lipophilic prodrug of PTX can improve its lipid solubility and affinity with self-microemulsion. The particle size of the microemulsion formed by the two paclitaxel prodrug self-microemulsification concentrates after self-emulsification is between 200-250nm, PDI <0.4, and the particle size distribution is uniform. The above results show that the average particle size of the droplets obtained after the self-emulsification of the prepared preparations is small and easy to be absorbed by the body.

[0084] Table 2 Composition and dispersion of PTX and its prodrug self-microemulsion

[0085]

[0086] Example 4

[0087] Pharmacokinetics of Paclitaxel-Fatty Acid Prodrug Self-Microemulsion Formulation

[0088] SD rats were used as animal models. PTX solution, PTX self-microemulsion, PTX-SS-OA self-microemulsion, and PTX-SS-LA self-microemulsion were gavaged at a dose of 10 mg / kg. Blood was collected from the orbits at regular intervals to determine the plasma concentration of paclitaxel parent drug at different time points. The drug-time curves were drawn and the corresponding pharmacokinetic parameters were calculated based on the measured concentrations. In order to calculate the absolute bioavailability, TAXOL was administered intravenously at a dose of 5 mg / kg, and the paclitaxel content in plasma was determined. Figure 7 As shown in Table 3, when administered orally, the peak concentrations of C max The t of PTX-SS-OA SMEDDS and PTX-SS-LA SMEDDS was greater than that of paclitaxel oral self-microemulsion group and paclitaxel solution group. 1 / 2 The total oral absolute bioavailability of PTX-SS-OA SMEDDS and PTX-SS-LA SMEDDS was 37.2% and 36.5%, respectively.

[0089] Table 3 Pharmacokinetic parameters of paclitaxel-fatty acid prodrugs

[0090]

[0091] Example 5

[0092] Pharmacodynamics of Paclitaxel-Fatty Acid Prodrug Self-Microemulsion Formulation

[0093] Using 4T1-bearing Balb / C female mice as a model, PTX solution (10 mg / kg), PTX oral self-microemulsification solution (10 mg / kg), PTX-SS-OA SMEDDS (PTX equivalent dose 10 mg / kg), PTX-SS-LA SMEDDS (PTX equivalent dose 10 mg / kg) were orally administered once a day; TAXOL (10 mg / kg) was intravenously injected at an interval of 2 days; and the normal saline group was used as a blank control. As shown in Figure 8, the tumor volume of the paclitaxel-fatty acid prodrug self-microemulsification group was the smallest, with significant differences from the control group, and there was no weight loss, indicating that it has reliable safety and good anti-tumor effect.

Claims

1. A self-microemulsification preparation of paclitaxel-fatty acid prodrug, characterized in that: It is composed of paclitaxel-fatty acid prodrug and excipients. The paclitaxel-fatty acid prodrug is paclitaxel-oleic acid prodrug or paclitaxel-linoleic acid prodrug, and the structures are as follows: Wherein, the preparation method of paclitaxel-oleic acid prodrug comprises the following steps: (a) Oleic acid is dissolved in an organic solvent and reacted with ethylene glycol under the catalysis of p-toluenesulfonic acid to obtain an intermediate product 1; (b) dissolving 2,2'-dithiodiacetic anhydride in an organic solvent and reacting with the intermediate product 1 in the presence of HOBT, EDCI and DMAP to obtain the intermediate product 2; (c) esterification reaction of the intermediate product 2 with paclitaxel under the catalytic conditions of HOBT and EDCI, and separation and purification to obtain paclitaxel-oleic acid prodrug; The auxiliary materials include emulsifier, short-chain alcohol or ether emulsifier, and oil phase. By weight percentage, the oil phase accounts for 10%-70% of the self-microemulsification preparation, the emulsifier accounts for 15%-80% of the self-microemulsification preparation, the short-chain alcohol or ether emulsifier accounts for 0%-35% of the self-microemulsification preparation; and the paclitaxel-fatty acid prodrug accounts for 1%-10% of the total amount of the auxiliary materials; The oil phase is one or more of monoolein, monolinolein, caprylic capric macrogol glyceride, oleic acid macrogol glyceride, and tricaprylic acid glyceride; The short-chain alcohol or ether emulsifier is one of diethylene glycol monoethyl ether and propylene glycol monooctanoate; The emulsifier is selected from Tween 80, Tween 20 and Tween 60.

2. The self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 1, characterized in that: The oil phase accounts for 10%-60% of the self-microemulsification preparation, the emulsifier accounts for 25%-80% of the self-microemulsification preparation, the short-chain alcohol or ether emulsifier accounts for 0%-30% of the self-microemulsification preparation, and the paclitaxel-fatty acid prodrug accounts for 1%-5% of the total amount of excipients.

3. The self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 2, characterized in that: The weight ratio of oil phase, emulsifier, and short-chain alcohol or ether emulsifier is 3:(10-20):(2-6); The oil phase is monolinoleyl glyceride; The short-chain alcohol or ether emulsifier is diethylene glycol monoethyl ether; The emulsifier is Tween 80.

4. The self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 1, characterized in that: The oil phase is monolinoleyl glycerol, the emulsifier is Tween 80, the short-chain alcohol or ether emulsifier is diethylene glycol monoethyl ether, and the oil phase accounts for 10%-70% of the self-microemulsification preparation, the emulsifier accounts for 15%-80% of the self-microemulsification preparation, and the short-chain alcohol or ether emulsifier accounts for 0%-35% of the self-microemulsification preparation.

5. Use of the self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 1 in the preparation of oral medicaments.

6. Use of the self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 1 in the preparation of anti-tumor drugs.

7. Use of the self-microemulsification preparation of paclitaxel-fatty acid prodrug according to claim 1 in preparing a drug delivery system.

Citation Information

Patent Citations

  • Decataxel self-microemulsifying composition and preparation method thereof

    CN101579310A

  • Taxol nano-self-microemulsion and preparation method thereof

    CN101829055A

  • Construction of paclitaxel-oleic acid small-molecular prodrug self-assembled nanoparticles

    CN105833284A

  • Construction of self-assembled nanoparticles of paclitaxel-oleic acid small molecule prodrug

    CN105833284B